Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MagnetisMM-5 in relapsed/refractory multiple myeloma
NL-OMON60155Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of elranatamab in multiple myeloma (MM), sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities, Progression-free survival and 1 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON60155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60155.